Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Receives Publication through American Chemical Society for KLS-13019, a Novel Cannabidiol-Derived Target Drug Candidate for Hepatic Encephalopathy

Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Receives Publication through American Chemical Society for KLS-13019, a Novel Cannabidiol-Derived Target Drug Candidate for Hepatic Encephalopathy

Kannalife Sciences, Inc., a Phyto-Medical Company™ has found through its research that KLS-13019 is 50x More Potent and Over 400-Fold Safer Than CBD SAN DIEGO, CA – February 18, 2016 – Medical Marijuana, Inc. (OTC Pink: MJNA) is pleased to announce that the Company’s...